Cargando…

Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

Detalles Bibliográficos
Autores principales:	Capoferri, Gioele, Walti, Carla Simone, Urwyler, Pascal, Ragozzino, Silvio, Passweg, Jakob R., Halter, Jörg, Battegay, Manuel, Baettig, Veronika, Weisser, Maja, Arnold, Brice, Morin, Benedict, Guetlin, Yukino, Torres, Diana Albertos, Barut, Güliz Tuba, Thiel, Volker, Egli, Adrian, Drexler, Beatrice, Khanna, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933011/ https://www.ncbi.nlm.nih.gov/pubmed/36797421 http://dx.doi.org/10.1038/s41409-023-01936-2

Ejemplares similares

Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation
por: Mauramo, Matti, et al.
Publicado: (2019)

Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
por: Spahr, Yasmin, et al.
Publicado: (2018)

Relative bradycardia in patients with COVID-19
por: Capoferri, Gioele, et al.
Publicado: (2021)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
por: Rockett, Rebecca, et al.
Publicado: (2022)

Antibody response to mRNA SARS‐CoV‐2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation
por: Beerlage, Astrid, et al.
Publicado: (2022)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Single-cell transcriptomics reveals striking heterogeneity and functional organization of dendritic and monocytic cells in the bovine mesenteric lymph node
por: Barut, Güliz Tuba, et al.
Publicado: (2023)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
por: Murase, Kazuyuki, et al.
Publicado: (2023)

Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis
por: Capoferri, Gioele, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection
por: Weber, Sven C., et al.
Publicado: (2022)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
por: Yoshida, Junichi, et al.
Publicado: (2022)

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
por: Rasmussen, Line Dahlerup, et al.
Publicado: (2023)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
por: Marzolini, Catia, et al.
Publicado: (2020)

Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation
por: Egli, A., et al.
Publicado: (2012)

Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia
por: Søgaard, Kirstine K., et al.
Publicado: (2021)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
por: Jungius, Sarah, et al.
Publicado: (2023)

Case report: when two and ½ men go camping…
por: von Rotz, Matthias, et al.
Publicado: (2017)

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
por: Stiasny, Karin, et al.
Publicado: (2022)

Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study
por: Junker, Till, et al.
Publicado: (2023)

Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
por: Héritier, Jérémie, et al.
Publicado: (2022)

“Titer of anti-HBs in health professions trainees: prevalence of antibody coverage in a University of Central Italy”
por: Di Giampaolo, Luca, et al.
Publicado: (2021)

Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
por: Elesdoudy, Ahmed
Publicado: (2021)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pr4asb4a158hfkob0jn2ptl7sm